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Summary: Sodium and potassium were measured in sets of 102 to 107 patients sera, and in 31 commercially
available control sera. The results from four routine analytical methods/systems (indirect potentiometry: two; direct
potentiometry and enzymatic assay: one each) were compared with those from a flame photometry-based reference
method. In the assay of patient sera, substantial agreement was observed in some comparisons, clinically relevant
bias in others. The inter-assay changes observed for the control sera differed significantly from those shown by the
patients sera (i.e. commercial control sera were non-commutable) in about 12% of the comparisons, as a whole.
Recalculation of serum sample results with a single control serum as calibrator lowered or increased the bias
originally present according to whether the serum itself was commutable or not. Moreover, the inter-method variabil-
ity in the assay of commercial control sera was lower with commutable sera, higher with non-commutable sera.
With the exception of liquid sera stabilized with ethylene glycol, there was no evident link between any specific
characteristic of the commercial control sera (matrix and physical state) and their degree of commutability.
Introduction
Methods based on "indirect" potentiometry (diluted
sample), with ion-selective electrodes, are widely used
for the clinical measurement of sodium and potassium
in serum. Alternative analytical approaches include "di-
rect" potentiometry (undiluted sample), also widely used
(1), and enzyme activation-based photometric methods
(2, 3). Flame atomic emission photometry is mainly
used for reference purposes (4).
The very low intra-individual biological variation of se-
rum sodium and potassium (5) requires accurate mea-
surements (6, 8). On the other hand, methods based on
different principles may be expected to give different
results, more so if the different methods respond to dif-
ferent, although related, quantities, either substance con-
centration or ion activity (1). It has been suggested that
method-dependent results be equalized by making them
consistently traceable to flame photometry, by means of
adequate calibration processes, in spite of different ana-
lytical principles and different quantities measured (1).
In practice, more or less extensively processed sera are
used in pursuing or monitoring trueness. The inter-
method behaviour of such commercially available sera
may differ from that of fresh patients sera. The term
"commutability" was first suggested to refer to "the
ability of an enzyme material to show inter-assay
changes comparable to those of patient sera " and it was
later extended to non-enzymic components in control
sera (9). Many commercially available control sera have
been shown to lack such a property (10, 11), and fresh-
frozen human serum proved to be the best material for
transferring the trueness from reference to ion-selective
electrode measurements of sodium and potassium (1).
We assessed the trueness of some routine measurement
procedures by comparison with flame emission photo-
metry, and we compared the inter-method behaviour of
a number of commercially available control sera to that
of patients sera. The effect of commutability of such sera
on the trueness of routine results after recalibration, and
on the inter-laboratory (inter-method) variability in their
assay, was also evaluated.
Materials and Methods
Sets of 102 to 107 fresh patient serum samples, covering wide
ranges of sodium and potassium concentrations, and 31 commer-
cially available control sera were used in each comparison experi-
ment (see tab. 2).
The routine measurements were performed with the following four
methods/instruments/systems.
Method 1
Indirect potentiometry, E2A instrument, from Beckman, reagents
and calibrators from the same source.
Method 2
Indirect potentiometry, Hitachi 717 analyzer, from Boehringer
Mannheim, reagents and calibrators from the same source.
Method 3
Direct potentiometry, Cobas Mira S plus analyzer, from Roche,
reagents and calibrators from the same source.
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Method 4
Enzymatic-photometric, Cobas Mira S plus analyzer, from Roche,
reagents and calibrators from Boehringer Mannheim, based on acti-
vation of -galactosidase1) by Na+ ions (2) and of pyruvate ki-
nase1) by K+ ions (3), respectively.
The reference methods, based on flame atomic emission photome-
try, were performed essentially as described (4), including bracket-
ing calibration, with the main modification that caesium instead of
lithium was used as the internal standard: an IL 943 instrument,
from Instrumentation Laboratory, was used.
The control sera were assayed in triplicate.
The within-run analytical imprecision of each method, as CV (%),
was calculated from replicate measurements on the control sera.
The relationship between the results from each routine method (as-
signed the y-axis) and the reference method values (assigned the
x-axis) was assessed by means of non-parametric linear regression
(12, 13). The dispersion around the regression line was estimated
as residual standard deviation (Syx); correlation coefficients (r)
were also calculated. The regression equations were used to calcu-
late the relative (percent) bias of the routine methods versus the
reference method at three clinically important decision values.
For each control serum, in each pair of methods, the residual (dis-
tance from the regression line along the y-axis) was computed, and
divided by the residual standard deviation, to yield the normalized
residual of the control serum, in standard deviation units (SD
units): this was taken as the measure of its degree of commutability
(9). A normalized residual outside the ± 3.0 SD units interval
means a very low probability for a control serum to share the same
inter-method behaviour with the patients sera's population, and
therefore is taken to mean lack of commutability.
To assess the effect of recalibration with a given control serum,
the results for a whole set of patients' sera with a stated routine
method were recalculated, taking a control serum, with its conven-
tional true value as assigned by means of the reference method, as
the calibrator. The differences [(original routine value) — (refer-
ence method value)] and [(recalculated routine value) — (reference
method value)] were then computed, and the distributions of such
differences were displayed graphically, as empirical cumulative
distribution plots (unfolded) (14).
Results
The median within-run coefficients of variation of the





Corresponding figures for the reference method were
0.5%/0.5%.
The statistical assessment of method comparison results
is shown in table 1. In three out of four comparisons for
sodium, and in one out of four for potassium, the slope
values are significantly different from 1 (1 outside the
95% confidence interval of the slope). In such compari-
sons a y-intercept value significantly different from
0 mmol/1 (0 outside the 95% confidence interval of the
intercept) is also observed: this partially corrected the
') Enzymes
-Galactosidase: -D-Galactoside galactohydrolase, EC 3.2.1.12.
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effect of the slope, and therefore minimized the bias at
clinical decision levels (tab. 1). The dispersion around
the line, as measured by the residual standard deviation,
is rather constant in the different comparisons, with the
exception of potassium measurement with the enzy-
matic method.
The normalized residuals of the 31 control sera, in the 4
pairs of methods (the reference method values always
as the independent variable) are listed in table 2 (sodium
and potassium). As mentioned, control sera showing a
normalized residual outside the ± 3 SD unit interval
were classified as non-commutable. Occasionally, some
commercial control sera gave "absurd" values with one
or more methods: these too were classified as non-com-
mutable. Considering a total of 124 evaluations for each
analyte (31 control sera X 4 pairs of methods), the over-
all frequency of non-commutability was 14/124 (11.3%)
for sodium and 16/124 (12.9%) for potassium. The
higher rate of non-commutability of control sera was ob-
served for direct potentiometry (24.2%), followed by in-
direct potentiometry (8.9%) and by the enzymatic
method (6.4%). With the two analytical systems based
on indirect potentiometry, the frequency of non-commu-
tability of the control sera was respectively 17.7%
(equally divided between sodium and potassium) and
0%.
The inter-method behaviour of the commutable and non-
commutable control sera, in comparison with the rele-
vant regression line from patient sera results, is shown
in figure 1 (sodium) and figure 2 (potassium).
In order to exemplify the effect of recalibration with
commutable and non-commutable control sera, the
method showing the highest bias in the assay of patient
sera was chosen (direct potentiometry, see tab. 1). The
results generated by this method in the assay of patient
sera (n = 102) were recalculated, using respectively one
commutable and one non-commutable material as cali-
brators. Materials number 26 and 9 (normalized residu-
als 0.0 and 3.6) were chosen for sodium, and number 19
and 5 (normalized residual 0.2 and 7.9) were chosen for
potassium (tab. 2). Cumulative plots of the differences
versus the reference method values, before and after re-
Tab. 2 Main characteristics of the 31 commercially available control sera included in the study, and
relevant normalized residuals in 4 pairs of methods.
N Matrix Physical state Normalized residuals [SD units]
Method 1
Na
Method 2 Method 3
Na K Na K
stabilized with ethylene glycol
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Fig. 1 Intermethod behaviour of commutable (crosses) and non-
commutable (squares) control sera, compared with the regression
line from patient sera, in the measurement of sodium. Method 1
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Fig. 2 Intermethod behaviour of commutable (crosses) and non-
commutable (squares) control sera, compared with the regression
line from patient sera, in the measurement of potassium. Method 1
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and method 2: indirect potentiometry; method 3: direct potentiome-
try; method 4: enzymatic.
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Discussion
With the main exception of the enzymatic assay of so-
dium, within-run imprecision values generally approach
or fulfill the very stringent desirable analytical perform-
ance specifications derived from the biological variation
of the two analytes (6—8).
The bias between enzymatic and indirect potentiometric
measurements of sodium and potassium has been re-
-20 -15 -10 -5 Ο 5 10 15 20
Sodium [(direct potentlometry)-(reforence)] [ntmol/Q
100
-1 0 1
Potassium [(direct potentlometry)-(referenee)] [mmol/l]
Fig. 3 Cumulative distribution of the differences [(direct potenti-
ometry) - (reference method)] in the measurement of sodium (up-
per graph) and potassium (lower graph) in 102 samples of fresh
patient serum: b: original data; a: recalculated on the basis of a
commutable control serum; c: recalculated on the basis of a non-
commutable control serum.
Horizontal dotted lines are drawn at the 5th, 50th and 95th percen-
tiles.
calibration, are shown in figure 3. Clearly, the distribu-
tion's position (50th percentile) is improved (i.e.
brought nearer to zero) or worsened (i.e. made more
distant from zero) when either a commutable or a non-
commutable material is used for calibration.
The inter-laboratory (inter-methods) variation (as CV %)
in the measurement of both analytes in representative
sets of commutable and of non-commutable control sera
is shown in table 3: such variation appears lower in the
assay of the former control sera, higher in the assay of
the latter.
Tab. 3 Inter-laboratory (inter-method) variability (as CV %) ob-




6; 13; 19; 23
5; 9; 10; 12
13; 25; 27; 31






















a from table 2
the serum samples (15). However, in this study, the rela-
tive bias at clinically important decision levels of con-
centration often exceeds the recommended specifica-
tions (6, 8), especially in the measurement of sodium
(direct potentiometry) and of potassium (direct potenti-
ometry and enzymatic methods). In conjunction with un-
avoidable imprecision, such as bias may generate total
errors higher than the limits currently used in European
external quality assessment schemes, based on biologi-
cal variation (16). This points out the need for improving
the trueness of routine measurements, by improving
their traceability to flame emission photometry.
The observed bias may be corrected for by recalibration
with materials having values assigned by flame photo-
metry (1). For such a procedure to be effective, however,
the materials must show an interassay behaviour similar
to that of patient sera, i. e. they have to be commutable.
Examples given here show how the recalibration with
commutable control sera permits an almost complete cor-
rection of the original bias of a method (fig. 3). On the
other hand, about 12% frequency of non-commutability of
commercially available control sera was observed in this
study; the perverse effect of recalibrating with non-com-
mutable materials has also been exemplified (fig. 3).
Control sera similar to those included in the present
study are used in external quality assessment schemes.
Our data show that the inter-laboratory (inter-methods)
variability measured with such control sera varies as a
function of their degree of commutability (tab. 3), and
therefore may be not representative of the variability ob-
served in the assay of patient sera (17).
The reasons for the lack of commutability of the materi-
als are generally ascribed to the matrix, but they are
not always evident (17, 18). Modifications of the matrix
during the processing of commercial control sera may
contribute to non-commutability. The irregular behavi-
our of the sera stabilized with high concentrations of
ethylene glycol in direct potentiometry is a common ex-
perience. Also, replacement of bicarbonate by chloride
in some commercial sera has been reported to give un-
desirably high residual liquid junction potential with the
electrodes of dry-chemistry systems (Vitros analyzer,
formerly Ektachem), thereby producing spuriously ele-
vated values in sodium measurement (19). On the other
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hand, from our data (tab. 2), it is not easy to link the
irregular behaviour of any material either to the origin
of its matrix (human, animal or aqueous), or to its physi-
cal state (liquid or lyophilized). Furthermore, irregular
behaviour of a stated control serum was shown for either
of the two analytes or with either of the four methods
tested. With a few exceptions, the lack of commutability
seems therefore to represent an unpredictable event, due
to the interaction of the properties of the control serum
with the characteristics of the analytical system.
It seems reasonable to conclude that the commutability
of commercially available control sera in different pairs
or sets of methods should be tested if they are to be
successfully used either for external quality assessment
or for the calibration of methods, in order to make re-
sults consistently traceable to a common reference
method. Alternatively, target values adjusted for
method-material specific matrix effect should be
adopted in external quality assessment schemes (20, 21),
or fresh patients serum samples should be used. In fact,
liquid/frozen pools of non-modified human sera have
been satisfactorily used in several such schemes during
the last ten years (22).
All automatic systems are reported to show matrix ef-
fects for some analytes (20); in spite of some pessimistic
attitudes (20), efforts should be made to improve both
the robustness of the methods and the quality of the
control sera, in order to minimize the frequency of non-
commutability. One of the methods tested in the present
study (method 2), besides being the best aligned with
flame photometry in the assay of patient sera, as pre-
viously observed (15), was also sufficiently robust to
give consistent results in the assay of all the tested con-
trol sera.
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